155 related articles for article (PubMed ID: 22103902)
1. Characterization of adrenal metastatic cancer using FDG PET/CT.
Xu B; Gao J; Cui L; Wang H; Guan Z; Yao S; Shen Z; Tian J
Neoplasma; 2012; 59(1):92-9. PubMed ID: 22103902
[TBL] [Abstract][Full Text] [Related]
2. Utilisation of combined 18F-FDG PET/CT scan for differential diagnosis between benign and malignant adrenal enlargement.
Kim JY; Kim SH; Lee HJ; Kim MJ; Kim YH; Cho SH; Won KS
Br J Radiol; 2013 Aug; 86(1028):20130190. PubMed ID: 23833032
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of an adrenal mass in patients with non-small cell lung cancer by means of a normal range of adrenal standardized uptake values on FDG PET/CT.
Kim BS; Lee JD; Kang WJ
Ann Nucl Med; 2015 Apr; 29(3):276-83. PubMed ID: 25480483
[TBL] [Abstract][Full Text] [Related]
4. High False Positivity in Positron Emission Tomography is a Potential Diagnostic Pitfall in Patients with Suspected Adrenal Metastasis.
Lang BH; Cowling BJ; Li JY; Wong KP; Wan KY
World J Surg; 2015 Aug; 39(8):1902-8. PubMed ID: 25809060
[TBL] [Abstract][Full Text] [Related]
5. Fluorodeoxyglucose-positron-emission tomography/computed tomography imaging for adrenal masses in patients with lung cancer: review and diagnostic algorithm.
Stone WZ; Wymer DC; Canales BK
J Endourol; 2014 Jan; 28(1):104-11. PubMed ID: 23927734
[TBL] [Abstract][Full Text] [Related]
6. [Use of 18F-FDG-positron emission tomography in presurgical evaluation of nonspecific or suspectious adrenal masses in non-oncologic patients].
Pavón-Paz I; Rosado-Sierra JA; Balsa-Bretón MÁ; Guijarro-Armas G; Merino-Viveros M; Penín-Gonzalez FJ
Med Clin (Barc); 2016 Feb; 146(3):104-7. PubMed ID: 26343158
[TBL] [Abstract][Full Text] [Related]
7. (18)F-FDG PET versus (18)F-FDG PET/CT for adrenal gland lesion characterization: a comparison of diagnostic efficacy in lung cancer patients.
Sung YM; Lee KS; Kim BT; Choi JY; Chung MJ; Shim YM; Yi CA; Kim TS
Korean J Radiol; 2008; 9(1):19-28. PubMed ID: 18253072
[TBL] [Abstract][Full Text] [Related]
8. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
9. Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands.
Koopman D; van Dalen JA; Stigt JA; Slump CH; Knollema S; Jager PL
Ann Nucl Med; 2016 Feb; 30(2):145-52. PubMed ID: 26644009
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients.
Lu Y; Xie D; Huang W; Gong H; Yu J
Neoplasma; 2010; 57(2):129-34. PubMed ID: 20099976
[TBL] [Abstract][Full Text] [Related]
11. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI.
Yun M; Kim W; Alnafisi N; Lacorte L; Jang S; Alavi A
J Nucl Med; 2001 Dec; 42(12):1795-9. PubMed ID: 11752075
[TBL] [Abstract][Full Text] [Related]
14. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT.
Watanabe H; Kanematsu M; Goshima S; Kondo H; Kawada H; Noda Y; Moriyama N
Ann Nucl Med; 2013 Aug; 27(7):648-53. PubMed ID: 23625579
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.
Erasmus JJ; Patz EF; McAdams HP; Murray JG; Herndon J; Coleman RE; Goodman PC
AJR Am J Roentgenol; 1997 May; 168(5):1357-60. PubMed ID: 9129444
[TBL] [Abstract][Full Text] [Related]
16. Characterization of lipid-rich adrenal tumors by FDG PET/CT: Are they hormone-secreting or not?
Takanami K; Kaneta T; Morimoto R; Satoh F; Nakamura Y; Takase K; Takahashi S
Ann Nucl Med; 2014 Feb; 28(2):145-53. PubMed ID: 24272068
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
18. CT-guided percutaneous core biopsy for assessment of morphologically normal adrenal glands showing high FDG uptake in patients with lung cancer.
Chassagnon G; Bennani S; Freche G; Magdeleinat P; Mansuet-Lupo A; Revel MP
Br J Radiol; 2018 Dec; 91(1092):20180090. PubMed ID: 29906237
[TBL] [Abstract][Full Text] [Related]
19. The value of adding (18)F-FDG PET/CT to adrenal protocol CT for characterizing adrenal metastasis (≥ 10 mm) in oncologic patients.
Park SY; Park BK; Kim CK
AJR Am J Roentgenol; 2014 Feb; 202(2):W153-60. PubMed ID: 24450697
[TBL] [Abstract][Full Text] [Related]
20. Unilateral adrenal metastasis from non–small-cell lung cancer demonstrating very high FDG uptake with a standardized uptake value in excess of sixty.
Shawgi M; James J; Prescott M; McWilliam L
Clin Nucl Med; 2012 Aug; 37(8):812-4. PubMed ID: 22970434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
